Industry News

Drugmakers are seeking to limit their reliance on Chinese contractors who produce drugs used in clinical trials and early-stage manufacturing, a move that is benefiting rivals in India, according to interviews with 10 industry executives and experts.

Cell Biology Lab was inaugurated at Kumar Organic Products Research Centre on 15th November 2023 by Prof. Dr. Samir K Brahmachari , Former Director General, CSIR.

Biocon Biologics Limited a subsidiary of Biocon Ltd. has announced that MHRA, Medicines and Healthcare products Regulatory Agency in the UK, has granted marketing authorization for YESAFILI®, a biosimilar of Aflibercept.

In September, YESAFILI®, received marketing authorization approval from the European Commission (EC) for the European Union (EU).

Sage Therapeutics has priced the oral postpartum depression medicine at USD 15,900 for a full 14-day course of treatment which is developed with Biogen. The pricing of medicine has been announced recently, whereas the drug was approved by the FDA in August.

Zydus Lifesciences Limited a discovery-driven, global lifesciences company and Lupin Limited (Lupin), a global pharma major, announced that they have entered into a licensing and supply agreement to co-market, Saroglitazar Mg for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato Hepatitis (NASH) in India. With a once daily, 4mg dose regimen, Saroglitazar Mg enables better compliance, reduces the pill burden and offers the patient more convenience.

Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

Sun Pharmaceutical Industries Limited and Zydus Lifesciences Limited announced that both companies have entered into a licensing agreement to co-market an innovative drug, Desidustat in India. Desidustat is first-of-its-kind oral treatment for anemia associated with Chronic Kidney Disease (CKD) in India.

Eisai Co., Ltd and Biogen Inc. announced today that Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 Lecanemab for Early Alzheimer's Disease: Long-Term Outcomes, Predictive Biomarkers and Novel Subcutaneous Administration" at the 16th annual Clinical Trials on Alzheimer's Disease (CTAD) conference held in Boston, Massachusetts, United States and virtually October 24-27, 2023.

Philogen S.p.A and Sun Pharmaceutical Industries Limited are pleased to announce positive results from the Phase III PIVOTAL trial in patients with locally advanced fully resectable melanoma (NCT02938299). The study compared neoadjuvant intratumoral Nidlegy™ (Daromun) followed by surgery (treatment arm) vs. surgery alone (control arm). Patients were allowed to receive approved adjuvant systemic therapies after surgery in both arms.